Related Experiment Video

Updated: Aug 24, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis

Gideon Nesher1, Yaakov Berkun, Michal Mates

  • 1Department of Internal Medicine, Shaare Zedek Medical Center, Jerusalem, Israel. nesher@inter.net.il

Arthritis and Rheumatism
|April 13, 2004
PubMed

Insights

Low-dose aspirin significantly reduced cranial ischemic complications, including visual loss and cerebrovascular accidents (CVAs), in patients with giant cell arteritis (GCA). This finding highlights aspirin

Area of Science:

  • Rheumatology
  • Neurology
  • Cardiology

Background:

  • Giant cell arteritis (GCA) is a leading cause of morbidity due to cranial ischemic complications like cerebrovascular accidents (CVAs) and acute visual loss.
  • Effective preventative strategies for these complications in GCA patients are crucial.

Purpose of the Study:

  • To evaluate the impact of low-dose aspirin on the incidence of cranial ischemic complications in patients diagnosed with GCA.
  • To assess whether aspirin use influences the occurrence of visual loss and CVAs in GCA.

Main Methods:

  • A retrospective study reviewing medical charts of 175 patients diagnosed with GCA between 1980 and 2000.
  • Data from 166 patients with at least 3 months of follow-up were analyzed.
  • Comparison of cranial ischemic complication rates between patients receiving low-dose aspirin and those not receiving it.

Main Results:

  • At GCA diagnosis, 36 patients (21%) were on low-dose aspirin (100 mg/day), primarily for ischemic heart disease.
  • Aspirin-treated patients had significantly lower rates of cranial ischemic complications at presentation (8% vs. 29%, P=0.01).
  • During follow-up, aspirin use was associated with a lower incidence of complications (3% vs. 13%, P=0.02) despite steroid therapy.

Conclusions:

  • Low-dose aspirin appears to decrease the rate of visual loss and CVAs in patients with GCA.
  • Aspirin may be a beneficial adjunctive therapy for preventing ischemic events in GCA patients.
  • Further prospective studies could confirm these findings and optimize aspirin's role in GCA management.
Abstract

Related Concept Videos

Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...